24 October 2019
Visiongain has launched a new pharma report Global Protein Expression Market Forecast to 2029: Cell-free Expression System, Prokaryotic/Bacterial Expression System, Yeast Cell Expression Systems, Algal-based Expression Systems, Insect Cell Expression Systems, Mammalian Cell Expression Systems, Reagents, Expression Vectors, Competent Cells, Instruments, Services, Therapeutic Applications, Industrial Application, Research Application, Pharmaceutical and Biotechnology Companies, Academic Research Institutes, Contract Research Organizations (CROs).
The global protein expression market is estimated at $1.8bn in 2018. Visiongain estimated that the prokaryotic expression system accounted for 40.0% of the global protein expression market.
The lead analyst of the report commented "Recombinant proteins will continue to be essential reagents for drug discovery projects in the future and that technological developments will emerge to match changes in demand or to keep in step with advances in other application areas. Another great opportunity for future growth in the protein expression market is provided by emerging countries, especially China and India. Their markets are growing at a faster rate than that of the developed Western markets.
The demand for expertise in recombinant protein expression development is another opportunity for the market, and this will allow smaller niche companies to compete with the large multinational CROs, resulting in more companies entering the market and more products and services being offered."
Leading companies featured in the report include Agilent Technologies, Bio-Rad Technologies, EMD Milipore, New England Biolabs, Inc., Oxford Expression Technologies, Ltd., Promega Corporation, Qiagen NV, Takara Bio, Inc., Thermo Fisher Scientific, Inc. and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The increasing rates of patent expiry lead to a counter-strategy of switching companies from Rx to OTC. In the US, according to the Consumer Healthcare Products Association, approximately 106 ingredients and dosage strengths have undergone a change from Rx to OTC to around 700 OTC products on the market.
23 September 2020
. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.
16 September 2020
Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.
14 September 2020
The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.